| ¿µ¹® | cardiotonic, cardiotonic agent | ÇÑ±Û | °½ÉÁ¦ |
|---|---|---|---|
| ¼³¸í | ½ÉÀåÀÇ ¼öÃà·ÂÀ» Áõ°¨½ÃŰ´Â ¾à¹°À» ¸»ÇÑ´Ù. ±âº»ÀûÀ¸·Î ½É±Ù¼öÃà·ÂÀ» Áõ°½ÃÄÑ ½ÉÀå¹ÚÃâ·®À» Áõ°¡½ÃŰ´Â ¾à¹°ÀÌ´Ù. °½É¹è´çü, Æ÷½ºÆ÷µð¿¡½ºÆ®¶ó¾ÆÁ¦ ¾ïÁ¦Á¦, ¾Æµå·¹³¯¸° ¥â¼ö¿ëüÀÛ¿ëÁ¦, Ç÷°üÈ®ÀåÁ¦ µîÀÌ ÀÖ´Ù. ´ëÇ¥ÀûÀÎ ¿¹·Î¼´Â µð°î½Å(digoxine) µîÀÇ µðÁöÅ»¸®½º(digitalis)°¡ ÀÖ´Ù. |
||
| ¿µ¹® | alkylating agent | ÇÑ±Û | ¾ËųȾ๰ |
|---|---|---|---|
| ¼³¸í | Ç×¾ÏÁ¦ÀÇ ÀÏÁ¾. ÀÌ»óÀûÀÎ Ç×¾ÏÁ¦´Â Á¤»óÀûÀÎ ¼¼Æ÷¿¡´Â ÇØ¸¦ ÁÖÁö ¾Ê°í ´ÜÁö ¾Ï¼¼Æ÷¿¡¸¸ Ä¡¸íÀûÀÎ È¿°ú¸¦ ³ªÅ¸³»¾ß ÇÑ´Ù. ÀÌ·¸°Ô ÇÏ·Á¸é ¾Ï¼¼Æ÷¸¸ÀÇ Æ¯ÀÌÇÑ Æ¯¼ºÀ» ÀÌÇØÇÏ°í ±×°÷¿¡¸¸ ÀÛ¿ëÇÏ´Â ¾à¹°À» °³¹ßÇØ¾ß ÇÑ´Ù. ÇöÀç ´ëºÎºÐÀÇ Ç×¾ÏÁ¦´Â ¾Ï¼¼Æ÷°¡ Á¤»ó ¼¼Æ÷¿¡ ºñÇÏ¿© ¿ùµîÈ÷ Áõ½ÄÀ» »¡¸®ÇѴٴ Ư¼ºÀ» ÀÌ¿ëÇϰí ÀÖ´Ù. Áõ½ÄÀÌ ºü¸£´Ù´Â °ÍÀº ´Ù½Ã ¸»Çϸé À¯Àü Á¤º¸¸¦ °¡Áö°í ÀÖ´Â DNAÀÇ º¹Á¦°¡ ºü¸£´Ù´Â °ÍÀ» ÀǹÌÇÑ´Ù. ¸¸¾à DNAÀÇ º¹Á¦¸¦ ¹æÇØÇÑ´Ù¸é Áõ½ÄÀÌ ¾ÆÁÖ ºü¸¥ ¾Ï¼¼Æ÷¿¡°Ô´Â Ä¡¸íÀûÀÌÁö¸¸ ¿µ¿øÈ÷ Áõ½ÄÀ» ÇÏÁö ¾Ê´Â DNAÀÇ º¹Á¦°¡ °ÅÀÇ ÇÊ¿ä¾ø´Â)½Å°æ¼¼Æ÷³ª Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿¡ ºñÇØ¼ ¾ÆÁÖ ´À¸° Á¤»ó¼¼Æ÷¿¡´Â °ÅÀÇ ¿µÇâÀ» ÁÖÁö ¸øÇÑ´Ù. ÇÏÁö¸¸ ½Åü¿¡¼µµ Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿Í ºñ½ÁÇÑ ¼öÁØÀ¸·Î ÀϾ´Â Á¤»óÀûÀÎ ¼¼Æ÷°¡ Àִµ¥ ±×°ÍÀº ¸Ó¸®Ä«¶ôÀ» ¸¸µå´Â ¸ð³¶¼¼Æ÷¿Í ¼ÒȰüÀÇ Á¡¸·À» ÀÌ·ç´Â ¼¼Æ÷¿Í Ç÷¾×ÀÇ ¼¼Æ÷¸¦ ¸¸µå´Â °ñ¼ö ¼¼Æ÷ÀÌ´Ù. ±×·¯¹Ç·Î Ç×¾ÏÁ¦¸¦ »ç¿ëÇÒ °æ¿ì ¾Ï¼¼Æ÷¿Í ¸¶Âù°¡Áö·Î ÀÌµé ¼¼Æ÷µµ ÇÔ²² Ä¡¸íÀûÀÎ ¿µÇâÀ» ÀÔÀ» °ÍÀº ´ç¿¬ÇÏ´Ù(±×·¡¼ Ç×¾ÏÁ¦ Ä¡·á½Ã¿£ ¸Ó¸®°¡ ºüÁö°í ¼ÒȺҷ®ÀÌ Àß ¿Â´Ù). ¾ËĮȾ๰ÀÇ °æ¿ì¿¡´Â DNA¿Í Á÷Á¢ °áÇÕÀ» ÇÏ¿© DNAÀÇ º¹Á¦¸¦ ¾ïÁ¦ÇÔÀ¸·Î½á Ç×¾ÏÁ¦ÀÇ ¿ªÇÒÀ» ¼öÇàÇÑ´Ù. |
||
| ¿µ¹® | anti-inflammatory agent | ÇÑ±Û | Ç׿°ÁõÁ¦, ¼Ò¿°Á¦, ¿°Áõ¾à |
|---|---|---|---|
| ¼³¸í | ±¹¼Ò¿¡ ÀÛ¿ëÇÏ¿© ¿°ÁõÀ» Ä¡·áÇÏ°í ¹æÁöÇÏ´Â ¾à. ¿°ÁõÀ» °¡¶ó¾ÉÈ÷´Â ¾àÀ» ¸»ÇÑ´Ù. Á¶Á÷À» ±äÃà-Ä¡¹ÐÇÏ°Ô ÇÏ¿© Àå¾×°ú Á¡¾×ÀÇ ºÐºñ¸¦ ÁÙÀ̰í, Ç¥¸é¿¡ ÀÖ´Â ÀÛÀº Ç÷°ü¿¡ ºóÇ÷À» ÀÏÀ¸ÄÑ ÃæÇ÷µÇ´Â °ÍÀ» ¹æÁöÇÔÀ¸·Î½á ¿°ÁõÀû º´º¯À» Á¦°ÅÇÏ¿© ¸ðµç Áõ¼¼¸¦ ¾ø¾Ø´Ù. ´ëºÎºÐÀÇ ¼ö·ÅÁ¦-¿ÏÈÁ¦-Áø¾çÁ¦°¡ ÀÌ¿¡ ¼ÓÇÑ´Ù. Áß¿äÇÑ ¼ººÐÀ¸·Î´Â ¾Ë·ç¹Ì´½-ºñ½º¹«Æ®-¾Æ¿¬-³³ÈÇÕ¹°(º´¹Ý-Æä¸£¸¶Åç-¾Æ¿¬È-¿¬´ç µî) µîÀÌ ÀÖ´Ù. ÀÛ¿ë¿¡ µû¶ó Ç׿°ÁõÁøÅëÁ¦¿Í Ç׿°ÁõÈ¿¼ÒÁ¦·Î ³ª´¶´Ù. |
||
| SMCA | smooth muscle contracting agent; suckling mouse cataract agent |
|---|---|
| LSH | lutein-stimulating hormone; lymphocyte-stimulating hormone |
| MSH | medical self-help; melanocyte-stimulating hormone; melanophore-stimulating hormone |
| OSF | organ system failure; osteoclast-stimulating factor; outer spiral fiber; overgrowth stimulating fact... |
| DTIC | Dimethyl Triazeno Imidazole Carboxamide ; Alkylating Agent |
| GM-CSF | Granulocyte colony-stimulating factor , granulocyte-macrophage colony-stimulating factor |
|---|---|
| G-CSF | Granulocyte-Macrophage Colony-Stimulating Factor , Granulocyte Colony-Stimulating Factor |
| a | Agent |
| CAA | Chicken anaemia agent |
| FWA | fluorescent whitening agent |
| appetite | Natural recurring desire for food. (12 Dec 1998) |
|---|---|
| appetite depressants | Agents that are used to decrease appetite. In man, tolerance to the appetite suppression develops rapidly. Hence, continuous weight reduction is not usually observed in obese individuals without dietary restrictions. (12 Dec 1998) |
| appetite juice | Gastric juice secreted upon the sight or smell of food and at the time of eating, influenced by the attractiveness of the food and delight in the food ingested; a conditioned reflex. (05 Mar 2000) |
| appetite regulation | Physiologic mechanisms which regulate or control the appetite and food intake. (12 Dec 1998) |
| appetite stimulants | Agents that are used to stimulate appetite. These drugs are frequently used to treat anorexia associated with cancer and aids. (12 Dec 1998) |
| adrenal androgen-stimulating hormone | A putative pituitary hormone that may be responsible for increased secretion of adrenal androgens at the time of puberty. (05 Mar 2000) |
| macrophage colony-stimulating factor | <growth factor> A glycoprotein growth factor that causes the committed cell line to proliferate and mature into macrophages. A cytokine synthesised by mesenchymal cells that stimulates pluripotent stem cells of bone marrow into differentiating towards the production of monocytes (mononuclear phagocytes). The compound stimulates the survival, proliferation, and differentiation of haematopoietic cells of the monocyte-macrophage series. It is a disulfide-bonded glycoprotein dimer with a mw of 70 kD and binds to a single class of high affinity receptor which is identical to the product of the c-fms proto-oncogene. See: colony-stimulating factors. Chemical name: Colony-stimulating factor 1 Acronym: M-CSF (12 Dec 1998) |
| receptors, colony-stimulating factor | Cell surface receptors for colony-stimulating factors, local mediators, and hormones that regulate the survival, proliferation, and differentiation of haemopoietic cells. (12 Dec 1998) |
| receptors, granulocyte-colony-stimulating factor | Receptors that bind and internalise granulocyte-colony-stimulating factor. Their mw is believed to be 150 kD. These receptors are found mainly on a subset of myelomonocytic cells. (12 Dec 1998) |
| receptors, granulocyte-macrophage colony-stimulating factor | Receptors that bind and internalise the granulocyte-macrophage stimulating factor. Their mw is believed to be 84 kD. The most mature myelomonocytic cells, specifically human neutrophils, macrophages, and eosinophils, express the highest number of affinity receptors for this growth factor. (12 Dec 1998) |
| receptors, macrophage colony-stimulating factor | Glycoproteins of mw 165 kD which are encoded by the c-fms proto-oncogene. The binding of csf-1 to its receptors activates an intrinsic tyrosine kinase activity resulting in autophosphorylation of the receptors on tyrosine, rapid receptor down-regulation, and phosphorylation of as yet unidentified physiologic substrates that initiate a mitogenic response. (12 Dec 1998) |
| melanocyte-stimulating hormone | <endocrinology> A releasing hormone produced in the mammalian hypophysis and related structures in lower vertebrates. Made up of _ MSH (1665D), the same as amino acids 1-13 of ACTH and _ MSH (18 amino acids, 22 in humans). Causes darkening of the skin by expansion of the melanophores but its role in mammals is unclear. Synonym: melanotropin. Acronym: MSH (22 Sep 2002) |
| granulocyte-colony-stimulating factor | <growth factor, haematology, oncology> A glycoprotein of 25 kD containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukaemic myeloid cell lines. A protein that stimulates the growth and maturation of granulocytes. It is used to promote the recovery of the white cells following chemotherapy. See: colony-stimulating factor. Acronym: G-CSF (12 Dec 1998) |
| granulocyte-macrophage colony-stimulating factor | <growth factor, haematology, oncology> An acidic glycoprotein of mw 23 kD with internal disulfide bonds. It is produced in response to a number of inflammatory mediators by mesenchymal cells present in the haemopoietic environment and at peripheral sites of inflammation. It stimulates the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from foetal liver progenitor cells. It also has some functional activities in mature granulocytes and macrophages. It is used to promote the recovery of the white blood cells following chemotherapy. Chemical name: Colony-stimulating factor 2 See: colony-stimulating factor. Acronym: GM-CSF (12 Dec 1998) |
| colony-stimulating factor | <cell biology> A glycoprotein growth factor that regulates the differentiation of particular cells. These substances act in either paracrine or autocrine fashion on marrow cells, appear to act synergistically and can exert actions on several lines of progenitor cells, and influence end cell function. These lymphokines induce the maturation and proliferation of white blood cells from the primitive cell types present in bone marrow such as the leucocyte, macrophage and monocyte lines. These substances can also be made by recombinant DNA technology for use clinically to speed bone marrow recovery typically following chemotherapy. Acronym: CSF (18 Jul 2002) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|